Eikon Therapeutics, Inc. EIKN
- Market cap
- $449.0M
- P/E
- 0.0×
Follow EIKN
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | 384 | 384 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | (244) | (324) |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (244) | (324) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 25 | 24 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (96.76) | (115.29) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (53.50) | (65.14) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | (33.66) | (16.15) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (87.15) | (81.29) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | (226.98) | (303.75) |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 3 | 3 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | (135) | (189) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | (85) | (47) |
Capex
|
|||
| — | — | — | — | — | — | — | — | (220) | (235) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 171 | 294 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | (221) | (336) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | (572) | (879) |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (61.45%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 45.99% |
ROE
|
|||
Eikon Therapeutics, Inc. (EIKN) Latest News
3 Sep
Eikon Therapeutics appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer. Chief Scientific Officer hire can shape research strategy and pipeline progress.
22 Aug
Eikon Therapeutics advances EIK1003 and EIK1004 as safer PARP1 inhibitors for cancer treatment. EIK1003 and EIK1004 mark major pipeline progress in oncology with potential to shift competitive positioning.
13 Aug
Eikon Therapeutics reported second quarter 2026 financial results and clinical updates. Quarterly financial results and clinical updates typically deliver performance data that moderately shapes near-term sentiment without redefining long-term trajectory.
11 Aug
Eikon Therapeutics selected a dose for its ongoing TeLuRide-006 adaptive Phase 2/3 trial of EIK1001 in advanced melanoma. Dose selection milestone in Phase 2/3 melanoma trial advances EIK1001 and is likely to influence company trajectory and investor sentiment.
27 Jul
Eikon Therapeutics dosed the first patient in TeLuRide-008, a registrational Phase 2/3 trial of EIK1001 in non-small cell lung cancer. Initiation of a registrational Phase 2/3 trial for EIK1001 advances Eikon Therapeutics toward potential regulatory approval and revenue in lung cancer.
20 Jul
Eikon Therapeutics secured acceptance of seven abstracts for presentation at the 2026 ESMO Congress. Abstract acceptances signal pipeline progress with moderate potential effects on oncology positioning.
30 May
Eikon Therapeutics presented data on its clinical-stage programs at the 2026 American Society of Clinical Oncology annual meeting. Clinical data presentations at ASCO can substantially affect biotech valuation and development trajectory.
11 May
Eikon Therapeutics released first quarter 2026 financial results along with clinical program updates. Quarterly financials combined with clinical updates typically produce moderate effects on company valuation and sentiment.
30 Mar
Eikon Therapeutics announced fourth quarter and full year 2025 financial results along with clinical and corporate updates. Quarterly financial results combined with clinical updates can moderately shift investor sentiment and near-term valuation.
4 Feb
Eikon Therapeutics priced its upsized initial public offering. Upsized IPO delivers major capital infusion and public market access with significant effects on financial position and trajectory.